 ASLAN Pharmaceuticals Ltd NASDAQ: ASLN has screened the first patient in its Phase 2b dose-ranging study of eblasakimab ASLAN004 in adults with moderate-to-severe atopic dermatitis AD. Eblasakimab is a monoclonal antibody targeting the IL-13 receptor. 